Financial Performance - The company reported a revenue of CNY 136.87 million for Q1 2023, representing a 19.79% increase compared to CNY 114.26 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 15.80% to CNY 45.05 million from CNY 53.50 million year-on-year[4]. - Revenue from non-COVID-19 prevention products was CNY 119.35 million, an increase of 32.37% year-on-year, while revenue from COVID-19 prevention products fell by 27.30% to CNY 17.52 million[4]. - Total operating revenue for Q1 2023 reached ¥136,865,462.92, an increase of 19.8% compared to ¥114,258,131.97 in the same period last year[15]. - Net profit for Q1 2023 was ¥42,917,350.22, a decrease of 19.6% from ¥53,416,447.82 in Q1 2022[16]. - Total comprehensive income for the first quarter was CNY 44,761,276.15, a decrease of 16.5% compared to CNY 53,404,116.95 in the previous period[17]. Cash Flow and Investments - The net cash flow from operating activities increased by 19.13% to CNY 43.68 million compared to CNY 36.66 million in the previous year[4]. - Cash inflow from operating activities totaled CNY 140,542,625.73, an increase of 18.6% compared to CNY 118,501,065.66[19]. - Cash outflow from operating activities rose to CNY 96,863,467.12, up 18.4% from CNY 81,836,230.28[19]. - Net cash flow from investing activities was negative at CNY -103,630,241.42, an improvement from CNY -708,628,997.78 in the previous period[20]. - The company reported cash inflow from investment activities of CNY 677,746,001.59, down 21.1% from CNY 859,338,417.54[20]. - Total cash outflow from investing activities was CNY 781,376,243.01, a decrease of 50.1% compared to CNY 1,567,967,415.32[20]. - Cash and cash equivalents at the end of the period decreased to CNY 373,088,562.49 from CNY 852,129,668.04, a decline of 56.2%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,436[8]. - The largest shareholder, Chen Yiding, holds 23.53% of the shares, totaling 18,827,168 shares[8]. - Shareholders' equity attributable to shareholders increased by 1.94% to CNY 2.61 billion from CNY 2.56 billion at the end of the previous year[4]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.77 billion, a 1.10% increase from CNY 2.74 billion at the end of the previous year[4]. - Total assets as of the end of Q1 2023 were ¥2,766,184,307.54, compared to ¥2,735,960,236.60 at the beginning of the year, indicating a slight increase of 1.1%[13]. - Total liabilities decreased to ¥149,891,559.21 from ¥167,253,156.96, a reduction of 10.4%[13]. - The company's equity attributable to shareholders increased to ¥2,612,922,271.33 from ¥2,563,204,428.74, reflecting a growth of 1.9%[13]. Research and Development - Research and development expenses increased to ¥28,785,836.45, compared to ¥22,542,358.36 in the previous year, reflecting a growth of 27.6%[16]. Earnings Per Share - Basic earnings per share decreased by 15.79% to CNY 0.3754 from CNY 0.4458 in the same period last year[4]. - Basic earnings per share decreased to CNY 0.3754 from CNY 0.4458, reflecting a decline of 15.5%[17]. Other Information - The company received government subsidies amounting to CNY 392,391.70 during the reporting period[6]. - Other comprehensive income after tax for Q1 2023 was ¥1,843,925.93, compared to a loss of ¥12,330.87 in the same period last year[16]. - The first quarter report was not audited[21].
百普赛斯(301080) - 2023 Q1 - 季度财报